Oncology News | pharmaphorum

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

FDA clears Servier's Tibsovo as first targeted drug for MDS

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs

GSK claims a first with Jemperli in endometrial cancer

ESMO: J&J’s Tagrisso challenge, and other highlights

FDA clears Servier's Tibsovo as first targeted drug for MDS

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

ESMO: Survival data mars Pluvicto prostate cancer trial

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks